These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 22759198

  • 1. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
    Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F.
    Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
    [Abstract] [Full Text] [Related]

  • 2. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
    Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F.
    Br J Clin Pharmacol; 2013 Nov; 76(5):776-86. PubMed ID: 23451769
    [Abstract] [Full Text] [Related]

  • 3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
    Yamahira N, Frost C, Fukase H, Yu Z, Wang J, Pursley J, LaCreta F, Hiraoka M.
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
    [Abstract] [Full Text] [Related]

  • 4. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
    Frost C, Garonzik S, Shenker A, Barrett YC, LaCreta F.
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):974-984. PubMed ID: 34342172
    [Abstract] [Full Text] [Related]

  • 5. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
    Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F.
    Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
    [Abstract] [Full Text] [Related]

  • 6. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y, Wang Z, Perlstein I, Wang J, LaCreta F, Frost RJA, Frost C.
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [Abstract] [Full Text] [Related]

  • 7. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.
    Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.
    Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, Zhang D, Byon W, Boyd RA, LaCreta F.
    Br J Clin Pharmacol; 2014 Oct; 78(4):877-85. PubMed ID: 24697979
    [Abstract] [Full Text] [Related]

  • 10. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S, Becka M, Hemmrich M.
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [Abstract] [Full Text] [Related]

  • 11. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
    Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE.
    Br J Clin Pharmacol; 2013 Dec; 76(6):908-16. PubMed ID: 23488672
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men.
    Kim J, Lee SH, Boyce M, Warrington S, Cho KH, Yoon SK, Park HD, Kim A.
    Xenobiotica; 2015 Dec; 45(8):663-71. PubMed ID: 25673087
    [Abstract] [Full Text] [Related]

  • 14. The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study.
    Garonzik S, Byon W, Myers E, Li X, Marchisin D, Murthy B.
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):561-567. PubMed ID: 31030414
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
    Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C.
    J Clin Pharmacol; 2016 May; 56(5):628-36. PubMed ID: 26331581
    [Abstract] [Full Text] [Related]

  • 17. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.
    Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, LaCreta F.
    Clin Ther; 2015 Aug; 37(8):1703-12. PubMed ID: 26188837
    [Abstract] [Full Text] [Related]

  • 18. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
    Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, Boyd RA, LaCreta F, Frost CE.
    J Clin Pharmacol; 2016 May; 56(5):637-45. PubMed ID: 26358690
    [Abstract] [Full Text] [Related]

  • 19. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
    Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, Frost C.
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):147-54. PubMed ID: 24277644
    [Abstract] [Full Text] [Related]

  • 20. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.
    Xuan D, McBride S, Wastall P, Porcari A, DiCarlo L, Boyd RA.
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):13-26. PubMed ID: 27119575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.